The staff of the Protein Purification Core (PPC) use a number of techniques for effective protein production. The PPC has access to a wide variety of tools for the expression of recombinant protein in bacteria(our primary expression system), including many types of plasmid expression vectors and specialized bacterial strains. There is a rather large collection of strains to choose from, with genetic defects that influence proteolytic activity, mRNA stability, membrane permeability, and intracellular redox potential. In addition, there are strains that overproduce protein disulfide isomerase, molecular chaperones, transfer RNAs, and redox enzymes for coexpression with target proteins. There is an equally large and diverse collection of bacterial plasmid vectors for recombinant protein expression. Many of these use the Gateway cloning technology (Life Technologies), making them quick and easy to use. The PPC staff has experience with all of the major regulatory systems (e.g., T7, tac, pBAD, trc, lambda PL) and various formats for the production of recombinant proteins (untagged or fused to MBP, GST, NusA, thioredoxin, His-tag, Arg-tag, FLAG-tag, biotin acceptor peptide, etc.) to make full use of these reagents. The PPC has recently established an insect cell protein production facility to compliment its bacterial production capability, using both the Bac-to-Bac baculovirus expression system (Invitrogen)and the Drosophila expression system (Life Technologies). Like most bacterial production, the insect cell facility utilize Gateway cloning technology to maximize productivity. The PPC plans to evaluate the flashBAC baculovirus expression system from Oxford Expression Technologies. Indications are that this system may be valuable for secretory and membrane-bound protein production, and may be a good complement for the Drosophila expression system. The PPC personnel are experienced with all standard chromatography techniques required for protein purification. The core maintains a full array of supplies necessary for ion exchange, hydrophobic interaction, lectin, hydroxyapatite, dye, size exclusion, and affinity chromatography. Materials for chromatofocusing are also on hand. In addition to purification technology, the staff is very knowledgeable of methods required to characterize recombinant protein products. Among those used are gel electrophoresis and isoelectric focusing, mass spectroscopy, western analysis, N-terminal sequencing, dynamic light scattering and analytical ultracentrifugation, and circular dichroism spectroscopy. For structural studies, the PPC has in place standard operating procedures for the production of isotopically enriched proteins for heteronuclear nuclear magnetic resonance experiments and selenomethionine-substituted proteins for crystallography. Methods have been established for bacteria that eliminate the need to change cell type by manipulating the medium formulation and induction parameters, and produce recombinant protein at levels equivalent to the wildtype expression. For those proteins that fail to crystallize, the core can perform limited proteolysis as a way to identify potential structural domains, providing the Macromolecular Crystallography Laboratory investigator additional avenues for structural studies. This method has been extensively used both analytically, and on a preparative scale to produce structural domains that can be purified using conventional chromatography. The core produces and maintains three different kinds of tobacco etch virus (TEV) protease that are used by the Macromolecular Crystallography Laboratory for in vitro cleavage of fusion proteins that contain an intervening protease recognition sequence. Available are an N-terminal tagged His7-TEV protease, an untagged TEV protease and a maltose binding protein-TEV protease fusion protein. All contain a mutation that minimizes autoinactivation. Each has its advantage depending on the design of the protein purification scheme. Similarly, the core produces and maintains two types of tobacco vein mottling virus (TVMV) protease also used for in vitro cleavage of fusion proteins. These are available as an N-terminal His6-tagged TVMV protease and an untagged TVMV protease. The protease recognition site is different from TEV protease and allows the use of both recognition sequences in a single fusion protein. As an alternative to these potyvirus proteases, the PPC has recently purified the human rhinovirus 3C protease (i.e., PreScission protease) using a bacterial expression plasmid obtained from Arie Geerlof (Helmholtz Center Munich, Institute of Structural Biology, Neuherberg, Germany). This protease has good activity even at 4C and will be quite useful in cleaving fusion proteins produced in several commercial vectors such as the pGEX-P series, pTriEx-9 and pET-47b(+). In addition, the PPC has also purified the glycosidases endo-beta-N-acetylglucosaminidase H and endo-beta-N-acetylglucosaminidase F1 using bacterial expression plasmids obtained from Daniel Leahy (Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland). These enzyme will be invaluable at removing asparagine-linked oligosaccharide side chains from glycoproteins produced by our insect cell production facility, which often impede the crystallization process. For FY2013, as part of our research support for the Macromolecular Crystallography Laboratory, the PPC has completed 39 cloning projects and performed 85 protein purification. In addition 99 insect cell protein productions at the pilot and preparative levels were completed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC011016-06
Application #
8763744
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$798,429
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Hogan, Megan; Bahta, Medhanit; Cherry, Scott et al. (2013) Biomolecular Interactions of small-molecule inhibitors affecting the YopH protein tyrosine phosphatase. Chem Biol Drug Des 81:323-33
Lountos, George T; Tropea, Joseph E; Waugh, David S (2013) Structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas' disease. Mol Biochem Parasitol 187:1-8
Raran-Kurussi, Sreejith; Tözsér, József; Cherry, Scott et al. (2013) Differential temperature dependence of tobacco etch virus and rhinovirus 3C proteases. Anal Biochem 436:142-4
Feng, Hanqiao; Jenkins, Lisa M Miller; Durell, Stewart R et al. (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 17:202-10
Jenkins, Lisa M Miller; Yamaguchi, Hiroshi; Hayashi, Ryo et al. (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry 48:1244-55
Tropea, Joseph E; Cherry, Scott; Waugh, David S (2009) Expression and purification of soluble His(6)-tagged TEV protease. Methods Mol Biol 498:297-307
Tu, Chao; Tropea, Joseph E; Austin, Brian P et al. (2009) Structural basis for binding of RNA and cofactor by a KsgA methyltransferase. Structure 17:374-85
Lountos, George T; Tropea, Joseph E; Zhang, Di et al. (2009) Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci 18:92-100
Sun, Ping; Tropea, Joseph E; Austin, Brian P et al. (2008) Structural characterization of the Yersinia pestis type III secretion system needle protein YscF in complex with its heterodimeric chaperone YscE/YscG. J Mol Biol 377:819-30
Gan, Jianhua; Shaw, Gary; Tropea, Joseph E et al. (2008) A stepwise model for double-stranded RNA processing by ribonuclease III. Mol Microbiol 67:143-54